Surgeons to Present Real-World Performance Data from First 3,800 CurvaFix Implants at Orthopaedic Trauma Association Annual Meeting
Company-sponsored session in Nashville will detail a 1.45% reported removal rate and review recently published clinical
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.
CurvaFix, Inc. will sponsor an industry session at the 42nd Annual Orthopaedic Trauma Association Meeting (OTA), Sept. 23-26 at the Music City Center in Nashville, where orthopedic trauma surgeons will present real-world performance data from the first 3,800 CurvaFix implants and review recently published clinical experience with the technology. The company will also exhibit at Booth #222.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260917016679/en/
Orthopedic trauma surgeons will present real-world performance data from the first 3,800 CurvaFix implants and review recently published clinical experience with the technology at the 42nd Annual Orthopaedic Trauma Association meeting, Sept. 24, 7:00 am CDT in Exhibit Hall Theater 2, Music City Center, Nashville.
Across the first 3,800 CurvaFix implants, placed by more than 200 surgeons, the reported removal rate is just 1.45%. At OTA, CurvaFix will provide a detailed look behind that number, with every reported removal tracked by reason, including malpositioning, conversion to total hip replacement, nonunion, implant backout and in vivo implant breakage. Reported removal rates include 0.03% for in vivo implant breakage, 0.05% for implant backout and 0.24% for implant malpositioning.* The session will be moderated by Samir Mehta, M.D., chief of the division of orthopedic trauma and fracture care in Pennsylvania.
“We’re proud of how CurvaFix is performing in some very difficult pelvic fractures,” said Mark Foster, CEO of CurvaFix. “As the first and only intramedullary nail designed for the pelvis, CurvaFix brings established principles of IM nailing to this challenging anatomy. That includes a practical rule in trauma surgery: don’t put in anything you can’t get out. We designed CurvaFix with careful consideration for both reliable fixation and removal if needed. These data reflect real-world experience across our first 3,800 implants, with very low reported implant failure rates that should give surgeons and patients greater confidence in CurvaFix.”
Brett Crist, M.D., professor of orthopedic surgery at the University of Missouri and director of the orthopaedic trauma fellowship, will present the removal data. “As surgeons, we want fixation we can trust in the operating room, and throughout a patient’s recovery,” said Dr. Crist. “With 3,800 implanted devices, we now have meaningful experience with CurvaFix, including how often implants are removed and why. When you put these data in the context of what we see historically with traditional pelvic fixation, I think the results are very compelling.”
The session will also highlight the growing body of published clinical evidence supporting CurvaFix. Nicholas F. Quercetti, D.O., will present on fixation across the pubic symphysis, drawing on two papers he coauthored that were published in OTA International in 2026. The first describes a percutaneous technique for crossing the symphysis to fix the anterior pelvic ring. The second is a technique guide and case series on trans-symphyseal fixation for complex anterior pelvic fractures.
The session will be held Thursday, Sept. 24, from 7:00 to 7:50 a.m. CDT in Exhibit Hall Theater 2 at the Music City Center.
About the CurvaFix IM and Low Profile Systems
CurvaFix brings established principles of intramedullary fixation to the curved anatomy of the pelvis. Its curved design follows nonlinear osseous corridors to provide minimally invasive, load-sharing fixation, while offering reliability in poor bone quality, and maneuverability around existing hardware and across complex fracture patterns.
CurvaFix is supported by seven published clinical articles and growing experience across fragility and insufficiency fractures, high-energy trauma and oncology.
Published experience includes immediate weight bearing as tolerated, early ambulation, procedural efficiency and reliable implant performance, all important considerations in helping pelvic fracture patients regain mobility and independence.
Introduced at OTA 2025, the CurvaFix Low Profile System advanced the technology with a 65% smaller implant head, redesigned percutaneous instrumentation, increased compression capability, implant lengths up to 210 mm and single-pass flexible reaming.
About CurvaFix, Inc.
CurvaFix, Inc. is a privately held medical device company headquartered in Kirkland, Wash. The company develops implantable technologies to improve fracture fixation in curved bones, focusing on fragility fractures of the pelvis and high-energy pelvic trauma. The CurvaFix IM System and CurvaFix Low Profile System have received 510(k) clearance from the U.S. Food and Drug Administration. For more information, visit www.curvafix.com.
*All removal, adverse events, and product performance data are logged and investigated through internal CurvaFix complaints and post-market surveillance processes, regardless of their origin or how they were communicated. Complaints are defined as “any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device after it is released for distribution”, and are collected from multiple sources including, but not limited to, CurvaFix employees, physician and hospital users, and patient contact. Each adverse event and product issue (“complaint”) has been assessed for reportability in accordance with the US FDA’s Medical Device Reporting requirements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260917016679/en/
Media gallery
